High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors
Open Access
- 10 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1), 1-14
- https://doi.org/10.1186/s13046-021-01851-8
Abstract
Background: Ferritin receptor (CD71) is an example of a very attractive cancer target, since it is highly expressed in virtually all tumor types, including metastatic loci. However, this target can be considered to be inaccessible to conventional target therapies, due to its presence in many healthy tissues. Here, we describe the preclinical evaluation of a tumor proteases-activatable human ferritin (HFt)-based drug carrier (The-0504) that is able to selectively deliver the wide-spectrum topoisomerase I inhibitor Genz-644282 to CD71-expressing tumors, preventing the limiting toxic effects associated with CD71-targeting therapies. Methods: CD71 expression was evaluated using flow cytometry and immunohistochemistry techniques. The-0504 antiproliferative activity towards several cancer cell lines was assessed in vitro. The-0504 antitumor efficacy and survival benefit were evaluated in different human tumors, which had been grown either as xenografts or patient-derived xenografts in mice. The-0504 toxicology profile was investigated in multiple-cycle repeat-dose study in rodents. Results: In vitro studies indicate that The-0504 is highly specific for CD71 expressing cells, and that there is a relationship between CD71 levels and The-0504 anticancer activity. In vivo treatments with The-0504 showed a remarkable efficacy, eradicating several human tumors of very diverse and aggressive histotypes, such as pancreas, liver and colorectal carcinomas, and triple-negative breast cancer. Conclusions: Durable disease-free survival, persistent antitumor responses after discontinuation of treatment and favorable toxicology profile make The-0504 an ideal candidate for clinical development as a novel, CD71-targeted, low-toxicity alternative to chemotherapy.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (16776, 18467, 15196)
- Ministero dell’Istruzione, dell’Università e della Ricerca (2017483NH8_005)
This publication has 44 references indexed in Scilit:
- Ferritin Nanocages To Encapsulate and Deliver Photosensitizers for Efficient Photodynamic Therapy against CancerACS Nano, 2013
- Magnetoferritin nanoparticles for targeting and visualizing tumour tissuesNature Nanotechnology, 2012
- SNPs in DNA repair or oxidative stress genes and late subcutaneous fibrosis in patients following single shot partial breast irradiationJournal of Experimental & Clinical Cancer Research, 2012
- An Iron Regulatory Gene Signature Predicts Outcome in Breast CancerCancer Research, 2011
- A new model of rectal cancer with regional lymph node metastasis allowing in vivo evaluation by imaging biomarkersBiomedicine & Pharmacotherapy, 2011
- Molecular and Cellular Pharmacology of the Novel Noncamptothecin Topoisomerase I Inhibitor Genz-644282Molecular Cancer Therapeutics, 2011
- Pediatric Blood & Cancer, 2011
- Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer TreatmentClinical Cancer Research, 2011
- Binding and uptake of H-ferritin are mediated by human transferrin receptor-1Proceedings of the National Academy of Sciences of the United States of America, 2010
- A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective studyBreast Cancer Research, 2008